Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral propranolol for retinopathy of prematurity
IRCT20100512003915N21Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of propranolol in retinopathy of prematurity (ROP) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Need to intervention (laser therapy or Avastin administration). Started Apr 2018; status: completed.
02
Drugs
propranolol
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on IRCT20100512003915N21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100512003915N21.